| Address: | 400 Oyster Point Blvd, South San Francisco, CA 94080, USA |
|---|---|
| Postal code: | 94080 |
| Phone: | (650) 745-8179 |
| Website: | http://www.vpd.net/ |
There are no reviews yet!
You can review this Business and help others by leaving a comment. If you want to share your thoughts about Velocity Pharmaceutical Development, use the form below and your opinion, advice or comment will appear in this space.
Take the first right onto Oyster Point Boulevard. You will drive approximately 1 mile on Oyster Point Boulevard until it dead ends. We are located in the building on the right.
About Velocity Pharmaceutical Development Llc is located at the address 400 Oyster Point Blvd in South San Francisco, California 94080. They can be contacted via phone at (650) 745-8179 for pricing, hours and directions.
Velocity Pharmaceutical Development, LLC company research & investing information. Find executives and the latest company news. Menu Search. Bloomberg. ... 650-273-5748. Fax: 650-745-8179.
Velocity Pharmaceutical Development. 400 Oyster Point Blvd Ste 202. South San Francisco, CA 94080-1918. Local: (650) 745-8179 ...
Wrong David Collier? ... Chief Executive Officer at Velocity Pharmaceutical Development LLC. Wrong David Collier? ... (650) 745-8179. Direct Phone:
Velocity Pharmaceutical Development 400 Oyster Point Blvd ... (650) 745-8179 Website. Menu & Reservations Make Reservations . Order Online Tickets ...
Velocity Pharmaceutical Development. Map & Directions. Be the first to review! ... (650) 745-8179. 7. YEARS IN BUSINESS. Add to mybook. This listing has been added to ...
Velocity Pharmaceutical Development in South San Francisco, CA -- Get driving directions to 400 Oyster Point Blvd, Ste 202 South San Francisco, CA 94080. Add reviews and photos for Velocity Pharmaceutical Development.
Velocity Pharmaceutical Development, LLC And Tigercat Pharma, Inc. Announce First Patient Dosed In Phase 2 Study Of VPD-737 In Prurigo Nodularis. 8/4/2014. Velocity Pharmaceutical Development, LLC And Tigercat Pharma, Inc. Announce Regulatory Clearance For Initiating Phase Ii Study With Vpd-737 In Prurigo Nodularis. 6/23/2014
View Matthew Kerby's business profile and see work history, affiliations and more.